Diabetes and chronic liver disease (CLD) commonly coexist and interact with each other. CLD can cause abnormalities in glucose metabolism, while diabetes accelerates progression of CLD. For compensated CLD, anti-diabetic treatment is similar to those without liver disease. In decompensated CLD, tight glycemic control is not the goal and insulin therapy requires careful monitoring to avoid hypoglycemia due to altered liver function and insulin metabolism.
1. There is a vicious cycle between diabetes and liver disease, as diabetes can cause liver damage and liver disease increases the risk of diabetes.
2. Hepatogenous diabetes differs from type 2 diabetes in that it has a lower risk of cardiovascular complications and less often a family history of diabetes.
3. Metformin is the preferred agent for managing diabetes in patients with nonalcoholic fatty liver disease (NAFLD) or advanced liver disease, while insulin is recommended for decompensated cirrhosis.
This document summarizes key findings from the IDF Diabetes Atlas 2021:
1) An estimated 537 million adults aged 20-79 have diabetes globally in 2021, representing 1 in 10 adults. 6.7 million deaths are attributed to diabetes each year.
2) The top 10 countries for number of adults with diabetes are China, India, USA, Brazil, Pakistan, Indonesia, Mexico, Egypt, Italy, and Bangladesh. The top countries for diabetes healthcare expenditure are USA, China, Japan, Germany, and India.
3) Diabetes prevalence is increasing worldwide, with the majority (75%) of people with diabetes living in low and middle income countries. Cardiovascular disease is the leading cause of death for people
[2015] the treatment of diabetes mellitus of patients with chronic liver diseaseAyman Alsebaey
Diabetes is common in patients with chronic liver disease and poses treatment challenges. Control of hyperglycemia is the goal but can be difficult to achieve due to irregular pharmacodynamic studies of antidiabetic drugs in these patients. Inhibitors of alpha-glucosidase like acarbose are preferred due to low liver toxicity. Metformin is generally safe except in decompensated patients. Insulin sensitizers and incretin therapies are also relatively safe options. Sulfonylureas and meglitinides should be avoided due to risk of hypoglycemia and hepatotoxicity. Insulin is often needed but requires close monitoring. Liver transplantation can cure hepatogenous diabetes in many cases.
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
This document discusses two case studies of patients with type 2 diabetes mellitus. For the first case, a 50-year old female patient with HbA1c of 8.5-9% on oral medications, the summary recommends starting basal insulin such as glargine or detemir 15-20 units at bedtime. For the second case, a 68-year old obese male patient with HbA1c of 10.5% on maximum oral medications, the summary recommends starting a total daily dose of insulin of 0.3-0.5 units/kg, starting with premixed insulin such as Mixtard 18/10 units. Both cases emphasize individualizing treatment targets and adjusting insulin doses based on self-
Diabetes is a disorder where the body cannot properly process sugar, and it affects over 170 million people worldwide. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Type 1 is an autoimmune disease where the immune system destroys insulin-producing cells, type 2 occurs when cells do not properly absorb sugar despite enough insulin production, and gestational diabetes affects pregnant women. Untreated diabetes can damage organs and systems throughout the body. Weight loss and exercise have been shown to help regulate blood sugar levels and reduce the risk of type 2 diabetes.
This document discusses the challenges of managing diabetes in patients with chronic kidney disease (CKD). It notes that diabetes is a leading cause of CKD progression and that CKD increases mortality risk in diabetes patients. Managing glucose levels in CKD patients is difficult due to risks of hypoglycemia from insulin clearance issues and need to adjust oral medications for kidney function. The CARMELINA trial demonstrated the renal safety of the DPP-4 inhibitor linagliptin in high cardio-renal risk patients, showing no increase in sustained decrease in eGFR or other renal outcomes compared to placebo over 2 years.
1. There is a vicious cycle between diabetes and liver disease, as diabetes can cause liver damage and liver disease increases the risk of diabetes.
2. Hepatogenous diabetes differs from type 2 diabetes in that it has a lower risk of cardiovascular complications and less often a family history of diabetes.
3. Metformin is the preferred agent for managing diabetes in patients with nonalcoholic fatty liver disease (NAFLD) or advanced liver disease, while insulin is recommended for decompensated cirrhosis.
This document summarizes key findings from the IDF Diabetes Atlas 2021:
1) An estimated 537 million adults aged 20-79 have diabetes globally in 2021, representing 1 in 10 adults. 6.7 million deaths are attributed to diabetes each year.
2) The top 10 countries for number of adults with diabetes are China, India, USA, Brazil, Pakistan, Indonesia, Mexico, Egypt, Italy, and Bangladesh. The top countries for diabetes healthcare expenditure are USA, China, Japan, Germany, and India.
3) Diabetes prevalence is increasing worldwide, with the majority (75%) of people with diabetes living in low and middle income countries. Cardiovascular disease is the leading cause of death for people
[2015] the treatment of diabetes mellitus of patients with chronic liver diseaseAyman Alsebaey
Diabetes is common in patients with chronic liver disease and poses treatment challenges. Control of hyperglycemia is the goal but can be difficult to achieve due to irregular pharmacodynamic studies of antidiabetic drugs in these patients. Inhibitors of alpha-glucosidase like acarbose are preferred due to low liver toxicity. Metformin is generally safe except in decompensated patients. Insulin sensitizers and incretin therapies are also relatively safe options. Sulfonylureas and meglitinides should be avoided due to risk of hypoglycemia and hepatotoxicity. Insulin is often needed but requires close monitoring. Liver transplantation can cure hepatogenous diabetes in many cases.
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
This document discusses two case studies of patients with type 2 diabetes mellitus. For the first case, a 50-year old female patient with HbA1c of 8.5-9% on oral medications, the summary recommends starting basal insulin such as glargine or detemir 15-20 units at bedtime. For the second case, a 68-year old obese male patient with HbA1c of 10.5% on maximum oral medications, the summary recommends starting a total daily dose of insulin of 0.3-0.5 units/kg, starting with premixed insulin such as Mixtard 18/10 units. Both cases emphasize individualizing treatment targets and adjusting insulin doses based on self-
Diabetes is a disorder where the body cannot properly process sugar, and it affects over 170 million people worldwide. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Type 1 is an autoimmune disease where the immune system destroys insulin-producing cells, type 2 occurs when cells do not properly absorb sugar despite enough insulin production, and gestational diabetes affects pregnant women. Untreated diabetes can damage organs and systems throughout the body. Weight loss and exercise have been shown to help regulate blood sugar levels and reduce the risk of type 2 diabetes.
This document discusses the challenges of managing diabetes in patients with chronic kidney disease (CKD). It notes that diabetes is a leading cause of CKD progression and that CKD increases mortality risk in diabetes patients. Managing glucose levels in CKD patients is difficult due to risks of hypoglycemia from insulin clearance issues and need to adjust oral medications for kidney function. The CARMELINA trial demonstrated the renal safety of the DPP-4 inhibitor linagliptin in high cardio-renal risk patients, showing no increase in sustained decrease in eGFR or other renal outcomes compared to placebo over 2 years.
This document provides guidelines for managing diabetes care in the hospital. The goals are to prevent hyperglycemia and hypoglycemia, promote short hospital stays, and ensure effective care transitions. It recommends using computerized order sets for glucose control and ordering an HbA1c test on admission. Target blood glucose levels are outlined for critically ill and non-critically ill patients. Insulin therapy guidelines, treating hypoglycemia, and managing special situations like steroids or enteral feeding are also covered.
This document discusses the management of diabetes in patients with concomitant liver disease. It notes that about half of patients with cirrhosis have diabetes due to insulin resistance caused by the liver disease. Lifestyle changes and metformin are recommended initially if liver disease is mild. Insulin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and thiazolidinediones may be used, with monitoring needed due to potential side effects or altered drug metabolism in liver disease. Insulin requirements can vary depending on the stage of liver disease.
Empagliflozin is an SGLT2 inhibitor that has shown cardiovascular benefits in clinical trials. SGLT2 inhibitors work by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion and reduced blood glucose levels. Empagliflozin in particular has demonstrated reductions in cardiovascular death and hospitalization for heart failure. However, SGLT2 inhibitors also carry risks like genitourinary infections and volume depletion that require monitoring. Overall, SGLT2 inhibitors provide an additional treatment option for type 2 diabetes that can help lower glucose levels while also reducing cardiovascular outcomes.
This document summarizes the LEADER trial which investigated the cardiovascular outcomes of treatment with liraglutide versus placebo when added to standard care in patients with type 2 diabetes at high risk of cardiovascular events. The trial found that over a median follow up of 3.8 years, liraglutide reduced the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo. Liraglutide also reduced nephropathy but increased gallbladder disease and led to more discontinuations due to side effects.
This document summarizes recent developments with SGLT2 inhibitors. It discusses their use in non-diabetic heart failure and kidney disease, where trials have shown benefits. Potential additional uses discussed include NAFLD, obesity, sleep apnea, and PCOS, though evidence is limited. Risks are discussed for using SGLT2 inhibitors in type 1 diabetes or with very low carb diets. In conclusion, SGLT2 inhibitors have cardio-renal-metabolic effects but significant challenges remain in establishing their role for various non-standard conditions.
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
This document discusses the role of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in managing type 2 diabetes. It provides background on the pathophysiology and progression of type 2 diabetes and limitations of older drug classes. It then describes the mechanisms and roles of the newer drug classes like SGLT-2 inhibitors in promoting urinary glucose excretion and GLP-1 agonists and DPP-4 inhibitors in augmenting the body's own incretin response. It also discusses ongoing cardiovascular outcome trials and FDA approvals of these newer agents.
Dr. Vivek Baliga discusses diabetic dyslipidemia and emerging concepts in its management. Non-HDL cholesterol is a better indicator of cardiovascular risk than LDL cholesterol. It encompasses all potentially atherogenic lipoproteins. Dual PPAR alpha/gamma agonists like saroglitazar can effectively control dyslipidemia and maintain glycemic control in patients with diabetes by reducing triglycerides and non-HDL cholesterol while improving other lipid and glucose parameters. Saroglitazar is approved in India for the treatment of diabetic dyslipidemia.
This document discusses diabetic nephropathy and chronic kidney disease in patients with diabetes. It notes that diabetic nephropathy is a leading cause of end-stage renal disease in the United States. It recommends annual screening for albuminuria and measuring creatinine to monitor kidney function. Intensive glucose control can help reduce risk of kidney complications. Medications like ACE inhibitors and ARBs may preserve kidney function for patients with modestly elevated albumin levels. Lifestyle changes like reducing protein intake and controlling blood pressure and cholesterol are also important aspects of management.
This document summarizes a presentation on diabetic nephropathy given by Dr. Jafar Al-Said at the GCC Diabetes Conference in Bahrain in March 2016. It discusses the epidemiology, pathogenesis, progression, diagnosis and management of diabetic nephropathy. Specifically, it covers topics such as the definition of diabetic nephropathy, risk factors contributing to its development like genetics and hemodynamics, pathological features, the relationship between diabetes, cardiovascular disease and chronic kidney disease, and treatment approaches including lifestyle modifications, blood pressure and glucose control, and use of RAAS inhibitors.
SGLT-2 inhibitors have shown promising cardiovascular and renal benefits:
1) Trials have found SGLT-2 inhibitors reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, as well as reducing heart failure hospitalizations in those with diabetes and cardiovascular risk factors.
2) Studies also show SGLT-2 inhibitors improve outcomes for patients with heart failure with reduced ejection fraction, reducing rates of heart failure hospitalization and mortality regardless of diabetes status or background heart failure therapies.
3) SGLT-2 inhibitors were also found to reduce the risk of renal death or progression to end-stage kidney disease in patients with type 2 diabetes and macroalbuminuria.
Ueda2016 symposium - glimepiride journey in management of type 2 dm - megahe...ueda2015
This document discusses glimepiride and its use in managing type 2 diabetes mellitus (T2DM). It begins with background on the global prevalence of diabetes and challenges in achieving glycemic control. It then focuses on glimepiride, explaining that it has a higher binding affinity and faster dissociation from sulfonylurea receptors compared to other sulfonylureas. This allows glimepiride to stimulate both the first and second phase of insulin secretion, improving fasting and postprandial hyperglycemia. In conclusion, glimepiride is an effective oral sulfonylurea option for the treatment of T2DM.
Dapagliflozin demonstrated clear treatment benefits for cardiovascular, kidney, and mortality outcomes in patients with chronic kidney disease (CKD), regardless of the presence of diabetes. It provides glomerular protection, limits proteinuria and kidney damage, and slows the decline of glomerular filtration rate in CKD patients. The DAPA-CKD trial found that dapagliflozin reduced the risk of end-stage renal disease or death from renal causes compared to placebo in CKD patients with and without type 2 diabetes. Dapagliflozin is indicated for the treatment of CKD up to stage III and was well tolerated with a low rate of treatment discontinuation.
The document summarizes clinical trials evaluating SGLT2 inhibitors:
1) The EMPA-REG trial found that empagliflozin reduced the risk of cardiovascular death, hospitalization for heart failure, and all-cause mortality compared to placebo in patients with type 2 diabetes at high cardiovascular risk.
2) The CANVAS trial found that canagliflozin reduced the risk of major adverse cardiovascular events and hospitalization for heart failure compared to placebo in patients with type 2 diabetes at high cardiovascular risk.
3) The DECLARE-TIMI 58 trial found that dapagliflozin did not increase the risk of major adverse cardiovascular events compared to placebo in patients with type 2 diabetes
Recent Advances in Obesity PharmacotherapyShreya Gupta
This document summarizes recent advances in obesity, including potential new drug targets. It discusses drugs currently in development like tesofensine, setmelanotide, semaglutide, and velneperitide that act on targets such as serotonin-norepinephrine-dopamine reuptake, melanocortin receptors, GLP-1 receptors, and neuropeptide Y receptors. The document also mentions exploring cannabinoid type 1 receptor blockers with limited brain penetration to avoid the psychiatric side effects that led to previous drugs being withdrawn.
http://www.theheart.org/web_slides/1135309.do
A study on Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients (ADVANCE)
This document discusses diabetic nephropathy, including its causes, risk factors, stages, diagnosis, progression, and treatment strategies. It notes that diabetic nephropathy is a major complication of diabetes and a leading cause of end-stage renal disease. Key points include that strict control of blood pressure, blood glucose, diet, and lifestyle factors can help prevent or slow the progression of kidney damage caused by diabetes.
DPP4 inhibitors have similarities such as sustained glucose lowering, minimal side effects, and weight neutrality. Differences include binding characteristics, with some binding longer to DPP4. Vildagliptin may provide better fasting glucose control due to maintaining overnight GLP1 levels. Vildagliptin has proven efficacy and safety in Ramadan fasting and has shown cardiovascular safety in clinical trials and real-world evidence, with no increased risk of heart failure unlike some other DPP4 inhibitors.
Are you Struggling to Control of your Diabetes and Weight?
People who are overweight or obese are more prone to developing Type 2 diabetes. Those who have Type 1 and Type 2 diabetes with weight problems struggle to control their blood sugar levels. Research shows that people with diabetes find it more difficult to lose weight than those without diabetes.
Weight loss significantly improves blood sugar control and also reduces the risk of getting complications from diabetes. However, whilst attempting to lose weight, people with diabetes find it hard to restrict their intake of food since eating less may trigger hypoglycaemia (low blood sugar). All these facts explain the need for specialist input in management of weight in people with diabetes.
This Slideshow gives you insight to Diabesity
For more information please visit
http://www.simplyweight.co.uk
Articles
http://www.simplyweight.co.uk/articles/
Videos
http://www.simplyweight.co.uk/video/
Blogs
http://simplyweight.co.uk/blogs/
Forum
http://www.simplyweight.co.uk/forum/forum.php
Contact Us
http://www.simplyweight.co.uk/how-to-contact-us/
This document summarizes a lecture on the roles of muscle, white adipose tissue (WAT), and liver in metabolic flexibility. It discusses how these tissues function normally and how dysfunctions can lead to conditions like fatty liver disease. Specifically, it describes:
1) The normal functions of muscle, WAT, and liver related to metabolism and how dysfunctions can cause diseases.
2) Studies on non-alcoholic fatty liver disease (NAFLD) and how communication between WAT and liver is essential for lipid storage.
3) Research on the effects of high-protein diets on hepatic lipid accumulation and gene expression changes in the gut-liver axis.
4) How exercise increases heart rate
Fatty liver disease with Diabetes Mellitus [BANGLADESH]drsamianik
A 52-year-old female with diabetes and hypertension for several years was found to have fatty liver disease based on elevated liver enzymes and ultrasound findings. She had overweight and mild liver enlargement but no signs of cirrhosis. Fatty liver disease is common in people with diabetes and obesity, as excess fat can accumulate in the liver. Lifestyle changes like weight loss and exercise through diet modification are the primary treatments recommended. Medical therapies for diabetes may also help improve fatty liver condition.
This document provides guidelines for managing diabetes care in the hospital. The goals are to prevent hyperglycemia and hypoglycemia, promote short hospital stays, and ensure effective care transitions. It recommends using computerized order sets for glucose control and ordering an HbA1c test on admission. Target blood glucose levels are outlined for critically ill and non-critically ill patients. Insulin therapy guidelines, treating hypoglycemia, and managing special situations like steroids or enteral feeding are also covered.
This document discusses the management of diabetes in patients with concomitant liver disease. It notes that about half of patients with cirrhosis have diabetes due to insulin resistance caused by the liver disease. Lifestyle changes and metformin are recommended initially if liver disease is mild. Insulin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and thiazolidinediones may be used, with monitoring needed due to potential side effects or altered drug metabolism in liver disease. Insulin requirements can vary depending on the stage of liver disease.
Empagliflozin is an SGLT2 inhibitor that has shown cardiovascular benefits in clinical trials. SGLT2 inhibitors work by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion and reduced blood glucose levels. Empagliflozin in particular has demonstrated reductions in cardiovascular death and hospitalization for heart failure. However, SGLT2 inhibitors also carry risks like genitourinary infections and volume depletion that require monitoring. Overall, SGLT2 inhibitors provide an additional treatment option for type 2 diabetes that can help lower glucose levels while also reducing cardiovascular outcomes.
This document summarizes the LEADER trial which investigated the cardiovascular outcomes of treatment with liraglutide versus placebo when added to standard care in patients with type 2 diabetes at high risk of cardiovascular events. The trial found that over a median follow up of 3.8 years, liraglutide reduced the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo. Liraglutide also reduced nephropathy but increased gallbladder disease and led to more discontinuations due to side effects.
This document summarizes recent developments with SGLT2 inhibitors. It discusses their use in non-diabetic heart failure and kidney disease, where trials have shown benefits. Potential additional uses discussed include NAFLD, obesity, sleep apnea, and PCOS, though evidence is limited. Risks are discussed for using SGLT2 inhibitors in type 1 diabetes or with very low carb diets. In conclusion, SGLT2 inhibitors have cardio-renal-metabolic effects but significant challenges remain in establishing their role for various non-standard conditions.
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
This document discusses the role of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in managing type 2 diabetes. It provides background on the pathophysiology and progression of type 2 diabetes and limitations of older drug classes. It then describes the mechanisms and roles of the newer drug classes like SGLT-2 inhibitors in promoting urinary glucose excretion and GLP-1 agonists and DPP-4 inhibitors in augmenting the body's own incretin response. It also discusses ongoing cardiovascular outcome trials and FDA approvals of these newer agents.
Dr. Vivek Baliga discusses diabetic dyslipidemia and emerging concepts in its management. Non-HDL cholesterol is a better indicator of cardiovascular risk than LDL cholesterol. It encompasses all potentially atherogenic lipoproteins. Dual PPAR alpha/gamma agonists like saroglitazar can effectively control dyslipidemia and maintain glycemic control in patients with diabetes by reducing triglycerides and non-HDL cholesterol while improving other lipid and glucose parameters. Saroglitazar is approved in India for the treatment of diabetic dyslipidemia.
This document discusses diabetic nephropathy and chronic kidney disease in patients with diabetes. It notes that diabetic nephropathy is a leading cause of end-stage renal disease in the United States. It recommends annual screening for albuminuria and measuring creatinine to monitor kidney function. Intensive glucose control can help reduce risk of kidney complications. Medications like ACE inhibitors and ARBs may preserve kidney function for patients with modestly elevated albumin levels. Lifestyle changes like reducing protein intake and controlling blood pressure and cholesterol are also important aspects of management.
This document summarizes a presentation on diabetic nephropathy given by Dr. Jafar Al-Said at the GCC Diabetes Conference in Bahrain in March 2016. It discusses the epidemiology, pathogenesis, progression, diagnosis and management of diabetic nephropathy. Specifically, it covers topics such as the definition of diabetic nephropathy, risk factors contributing to its development like genetics and hemodynamics, pathological features, the relationship between diabetes, cardiovascular disease and chronic kidney disease, and treatment approaches including lifestyle modifications, blood pressure and glucose control, and use of RAAS inhibitors.
SGLT-2 inhibitors have shown promising cardiovascular and renal benefits:
1) Trials have found SGLT-2 inhibitors reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, as well as reducing heart failure hospitalizations in those with diabetes and cardiovascular risk factors.
2) Studies also show SGLT-2 inhibitors improve outcomes for patients with heart failure with reduced ejection fraction, reducing rates of heart failure hospitalization and mortality regardless of diabetes status or background heart failure therapies.
3) SGLT-2 inhibitors were also found to reduce the risk of renal death or progression to end-stage kidney disease in patients with type 2 diabetes and macroalbuminuria.
Ueda2016 symposium - glimepiride journey in management of type 2 dm - megahe...ueda2015
This document discusses glimepiride and its use in managing type 2 diabetes mellitus (T2DM). It begins with background on the global prevalence of diabetes and challenges in achieving glycemic control. It then focuses on glimepiride, explaining that it has a higher binding affinity and faster dissociation from sulfonylurea receptors compared to other sulfonylureas. This allows glimepiride to stimulate both the first and second phase of insulin secretion, improving fasting and postprandial hyperglycemia. In conclusion, glimepiride is an effective oral sulfonylurea option for the treatment of T2DM.
Dapagliflozin demonstrated clear treatment benefits for cardiovascular, kidney, and mortality outcomes in patients with chronic kidney disease (CKD), regardless of the presence of diabetes. It provides glomerular protection, limits proteinuria and kidney damage, and slows the decline of glomerular filtration rate in CKD patients. The DAPA-CKD trial found that dapagliflozin reduced the risk of end-stage renal disease or death from renal causes compared to placebo in CKD patients with and without type 2 diabetes. Dapagliflozin is indicated for the treatment of CKD up to stage III and was well tolerated with a low rate of treatment discontinuation.
The document summarizes clinical trials evaluating SGLT2 inhibitors:
1) The EMPA-REG trial found that empagliflozin reduced the risk of cardiovascular death, hospitalization for heart failure, and all-cause mortality compared to placebo in patients with type 2 diabetes at high cardiovascular risk.
2) The CANVAS trial found that canagliflozin reduced the risk of major adverse cardiovascular events and hospitalization for heart failure compared to placebo in patients with type 2 diabetes at high cardiovascular risk.
3) The DECLARE-TIMI 58 trial found that dapagliflozin did not increase the risk of major adverse cardiovascular events compared to placebo in patients with type 2 diabetes
Recent Advances in Obesity PharmacotherapyShreya Gupta
This document summarizes recent advances in obesity, including potential new drug targets. It discusses drugs currently in development like tesofensine, setmelanotide, semaglutide, and velneperitide that act on targets such as serotonin-norepinephrine-dopamine reuptake, melanocortin receptors, GLP-1 receptors, and neuropeptide Y receptors. The document also mentions exploring cannabinoid type 1 receptor blockers with limited brain penetration to avoid the psychiatric side effects that led to previous drugs being withdrawn.
http://www.theheart.org/web_slides/1135309.do
A study on Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients (ADVANCE)
This document discusses diabetic nephropathy, including its causes, risk factors, stages, diagnosis, progression, and treatment strategies. It notes that diabetic nephropathy is a major complication of diabetes and a leading cause of end-stage renal disease. Key points include that strict control of blood pressure, blood glucose, diet, and lifestyle factors can help prevent or slow the progression of kidney damage caused by diabetes.
DPP4 inhibitors have similarities such as sustained glucose lowering, minimal side effects, and weight neutrality. Differences include binding characteristics, with some binding longer to DPP4. Vildagliptin may provide better fasting glucose control due to maintaining overnight GLP1 levels. Vildagliptin has proven efficacy and safety in Ramadan fasting and has shown cardiovascular safety in clinical trials and real-world evidence, with no increased risk of heart failure unlike some other DPP4 inhibitors.
Are you Struggling to Control of your Diabetes and Weight?
People who are overweight or obese are more prone to developing Type 2 diabetes. Those who have Type 1 and Type 2 diabetes with weight problems struggle to control their blood sugar levels. Research shows that people with diabetes find it more difficult to lose weight than those without diabetes.
Weight loss significantly improves blood sugar control and also reduces the risk of getting complications from diabetes. However, whilst attempting to lose weight, people with diabetes find it hard to restrict their intake of food since eating less may trigger hypoglycaemia (low blood sugar). All these facts explain the need for specialist input in management of weight in people with diabetes.
This Slideshow gives you insight to Diabesity
For more information please visit
http://www.simplyweight.co.uk
Articles
http://www.simplyweight.co.uk/articles/
Videos
http://www.simplyweight.co.uk/video/
Blogs
http://simplyweight.co.uk/blogs/
Forum
http://www.simplyweight.co.uk/forum/forum.php
Contact Us
http://www.simplyweight.co.uk/how-to-contact-us/
This document summarizes a lecture on the roles of muscle, white adipose tissue (WAT), and liver in metabolic flexibility. It discusses how these tissues function normally and how dysfunctions can lead to conditions like fatty liver disease. Specifically, it describes:
1) The normal functions of muscle, WAT, and liver related to metabolism and how dysfunctions can cause diseases.
2) Studies on non-alcoholic fatty liver disease (NAFLD) and how communication between WAT and liver is essential for lipid storage.
3) Research on the effects of high-protein diets on hepatic lipid accumulation and gene expression changes in the gut-liver axis.
4) How exercise increases heart rate
Fatty liver disease with Diabetes Mellitus [BANGLADESH]drsamianik
A 52-year-old female with diabetes and hypertension for several years was found to have fatty liver disease based on elevated liver enzymes and ultrasound findings. She had overweight and mild liver enlargement but no signs of cirrhosis. Fatty liver disease is common in people with diabetes and obesity, as excess fat can accumulate in the liver. Lifestyle changes like weight loss and exercise through diet modification are the primary treatments recommended. Medical therapies for diabetes may also help improve fatty liver condition.
Clinical, laboratory and histological associations in clinical, laboratory an...Dr. sreeremya S
Clinical, laboratory and histological associations in clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease
- Diabetic kidney disease is a major cause of mortality and morbidity in patients with diabetes. It can progress from microalbuminuria to macroalbuminuria and decreased kidney function over many years.
- Risk factors include uncontrolled hypertension and hyperglycemia, genetics, obesity, and smoking. The pathogenesis involves hemodynamic changes, activation of metabolic pathways, growth factors, the renin-angiotensin system, and oxidative stress.
- Management involves tight glycemic and blood pressure control, lifestyle modifications like diet and exercise, and medications targeting glucose, blood pressure, lipids, and proteinuria. Dialysis and kidney transplantation are treatment options for end-stage kidney disease.
Liraglutide is a GLP-1 agonist that was evaluated in the LEADER trial involving 9,340 patients with type 2 diabetes at high risk for cardiovascular events. The trial found that over a median follow-up of 3.8 years, patients receiving liraglutide had lower rates of death from cardiovascular causes and non-fatal myocardial infarction compared to placebo. Liraglutide was also associated with weight loss, lower blood pressure and heart rate, and reduced risk of nephropathy and retinopathy.
Impact of patient counseling on diabetes mellitus patients in the territory c...SriramNagarajan17
This study assessed the impact of patient counseling on 80 diabetes patients in Erode district, India over 6 months. After counseling on diet, exercise, medications and lifestyle changes, patients showed improved fasting blood glucose levels, blood pressure, and body mass index. Specifically, fasting blood glucose decreased from 148.40 mg/dl to 128.40 mg/dl. Body mass index and blood pressure also slightly decreased. The results suggest that patient counseling is effective for improving health outcomes for diabetes patients by helping them better manage their condition.
This document discusses nonalcoholic fatty liver disease (NAFLD). It begins by explaining that NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis. Insulin resistance plays a key role in the metabolic abnormalities seen in NAFLD. The pathogenesis of NASH is not fully understood. Currently, there are no approved therapies, so treatment focuses on lifestyle modifications like weight loss and exercise to improve comorbidities. The prevalence of NAFLD is increasing due to the rising obesity epidemic.
This document discusses diabetes and new antidiabetic drugs. It notes that diabetes cases are rising significantly worldwide and that diabetes increases the risk of serious health complications. It describes the different types of diabetes and their presentations. It recommends screening guidelines for prediabetes and notes the importance of lifestyle changes to prevent progression to diabetes. It discusses treatment targets and factors like hypoglycemia. It also provides an overview of various drug classes used to treat diabetes, including their mechanisms and effects.
Diabetes and Its Cardiovascular Complications.pptxMuzammal Wattoo
This document discusses diabetes and its cardiovascular complications. It begins by defining diabetes and classifying its four main types. It then discusses how angiogenesis, lymphangiogenesis and dysfunctional endothelial cells contribute to vascular complications in diabetes. Specifically, it explores how this impacts wound healing, development of collateral blood vessels, pregnancy outcomes, transplant rejection, and endothelial repair capacity. It also notes that cardiovascular disease causes the majority of deaths in diabetic patients. The document further examines links between diabetes and retinopathy, cardiomyopathy, cancer risk and peripheral artery disease. It outlines several pathological factors and molecular mechanisms involved in diabetic complications.
Renal disease in diabetes from prediabetes to late vasculopathy complication...nephro mih
This document provides information about Prof Basset El Essawy's qualifications and a lecture on renal disease in diabetes. It discusses epidemiological data on diabetic kidney disease prevalence in the US, summarizes findings from large diabetes treatment trials, and defines insulin resistance and prediabetes. It also covers prediabetes and nephropathy, presents case studies, and examines insulin resistance and vascular calcification.
This document discusses a study evaluating the presence of isolated left axis deviation (LAD) in diabetic patients and its relationship to various factors. The study found LAD present in 35% of diabetic patients compared to 8% of controls, indicating structural heart disease. LAD was more common in type 2 diabetics, those with high triglycerides or BMI, but not related to HbA1c or duration of diabetes. The document provides background on diabetes, its classification and diagnostic criteria, complications, and goals for glycemic control according to the American Diabetes Association.
The document discusses insulin resistance (IR) from various perspectives. It begins by explaining the importance of understanding IR as a measurable parameter that can provide insights into various conditions. It then covers topics such as assessing IR, the epidemiology of IR, the role of IR in type 1 diabetes, metabolic syndrome, obesity, hypertension, polycystic ovarian syndrome (PCOS), and other issues. The document emphasizes that IR underlies many common health problems and that measuring and managing IR can help address these conditions clinically.
1) This document reviews the impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes patients.
2) It discusses the natural history and pathophysiology of type 2 diabetes, including the increased risk of cardiovascular complications.
3) The review examines the effects of various oral and injectable glucose-lowering drugs on established cardiovascular risk factors and long-term cardiovascular outcomes based on evidence from epidemiological studies and clinical trials.
This document discusses diabetes mellitus (DM), including the different types of DM, symptoms, causes, long-term effects, risk factors, and management strategies. It defines DM as a metabolic disorder characterized by high blood glucose levels due to defects in insulin production or action. The three main types of DM are type 1, type 2, and gestational diabetes. Management involves lifestyle changes like diet and exercise, oral medications, and sometimes insulin therapy, with the goal of controlling blood glucose levels to minimize health complications.
The document discusses the relationship between endocrine diseases and liver abnormalities. It notes that the liver plays a key role in hormone synthesis and metabolism, so liver diseases can impact endocrine function. Specific endocrine conditions like hypothyroidism, Cushing's syndrome, and growth hormone deficiency are linked to non-alcoholic fatty liver disease through mechanisms like insulin resistance and obesity. Altered levels of hormones like thyroid hormones, cortisol, sex hormones, leptin, and adiponectin may also contribute to fatty liver development. Screening for endocrine abnormalities should be considered for patients with cryptogenic liver diseases.
Dentists play a major role in providing oral care to patients with diabetes. They can detect undiagnosed cases of diabetes and refer patients to physicians for evaluation. Dentists can work with physicians, nutritionists, and dental hygienists to maintain patients' oral health and possibly improve their metabolic control of diabetes. By maintaining oral health and referring patients for evaluation of oral complications, dentists can help reduce the morbidity and mortality associated with diabetes.
Cardiovascular risk in patients with diabetes mellitusHany Ahmad
This document discusses cardiovascular risk in patients with diabetes mellitus. It notes that diabetes is considered a coronary artery disease equivalent and is a major risk factor for cardiovascular events. Patients with diabetes have significantly higher risks of coronary artery disease, heart failure, stroke and other vascular complications compared to those without diabetes. The document outlines the various modifiable and non-modifiable risk factors that further increase cardiovascular risk in patients with diabetes, including dyslipidemia, hypertension, obesity, and smoking. It summarizes the results of major clinical trials investigating the effects of intensive glycemic control on microvascular and macrovascular outcomes.
This document discusses insulin resistance (IR) and its relationship to various medical conditions. It begins by defining IR and explaining common methods to assess IR, such as HOMA-IR and QUICKI. It then discusses the epidemiology of IR and its role in conditions like type 1 diabetes, metabolic syndrome, non-alcoholic fatty liver disease, obesity, hypertension, polycystic ovarian syndrome, and others. Management strategies for IR are also reviewed. The document provides an overview of the importance of recognizing and addressing IR in clinical practice.
The document discusses the proposal to change the name of non-alcoholic fatty liver disease (NAFLD) to metabolic associated fatty liver disease (MAFLD). It notes that NAFLD's name does not accurately capture the metabolic nature of the disease. The name change was proposed by an international panel of experts and aims to reduce stigmatization and increase consideration of the disease. If adopted, MAFLD would be used instead of NAFLD to describe fatty liver disease associated with metabolic dysfunction. The document supports the name change as a way to properly frame the growing epidemic of this liver disease.
This document provides an overview of diabetic kidney disease (DKD). It discusses the epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and evidence related to DKD. Some key points include: DKD is the leading cause of kidney failure worldwide; hyperglycemia is the primary factor in its development; it can present with or without albuminuria; treatment involves glycemic control, blood pressure control, and RAAS inhibitors; landmark trials such as RENAAL and IDNT showed renoprotective effects of ACEIs and ARBs; and recent trials demonstrate kidney and cardiovascular benefits of SGLT2 inhibitors in DKD patients.
Ueda2016 workshop - hypoglycemia1 -lobna el toonyueda2015
This document discusses hypoglycemia in diabetes. It defines hypoglycemia and describes its prevalence, causes, and risk factors. It notes that hypoglycemia is more common in type 1 diabetes and with intensive diabetes control. The document outlines the symptoms of mild, moderate, and severe hypoglycemia and explains how the body normally protects against low blood sugar. However, in diabetes these protective mechanisms become impaired over time, increasing the risk of severe hypoglycemia. The document discusses hypoglycemia in the context of type 1 and type 2 diabetes and provides tips for prevention and management, including recognizing risk factors, treating the underlying cause, and adjusting medications and food intake. It focuses on strategies to prevent nocturnal hypoglycemia specifically
Ueda2016 new horizon in the management of dyslipidemia - diaa ewaisueda2015
1) PCSK9 inhibitors are a new class of drugs that lower LDL cholesterol by blocking the PCSK9 protein and preventing degradation of LDL receptors.
2) Clinical trials of the PCSK9 inhibitors evolocumab and alirocumab showed reductions of LDL cholesterol up to 60-70% and reduced cardiovascular events.
3) PCSK9 inhibitors are effective in lowering cholesterol in patients who cannot tolerate high intensity statins and in those with familial hypercholesterolemia. They are intended for use in addition to, not instead of, statin therapy.
Ueda2016 workshop - diabetes in the elderly - mesbah kamelueda2015
This document discusses diabetes management challenges in elderly patients. It notes that the prevalence of diabetes increases with age and peaks between 60-74 years of age. Screening and diagnosing diabetes in elderly patients can be difficult due to non-specific symptoms. Management goals aim to avoid hypoglycemia and other adverse drug reactions while controlling hyperglycemia and risk factors. The risk of hypoglycemia, functional decline, depression and other geriatric issues increases with age, requiring special consideration in diabetes management for frail elderly patients.
Ueda2016 woman’s health & diabetes - lobna el toonyueda2015
This document discusses how diabetes differs and is managed for women at various life stages including puberty, pregnancy, and menopause. It notes that diabetes has more severe health impacts and higher mortality for women compared to men. During puberty, diabetes can delay menarche and cause menstrual disturbances. Gestational diabetes requires screening and treatment during pregnancy to prevent complications for mother and baby. Women with a history of gestational diabetes have a high risk of developing type 2 diabetes later in life. The document provides guidance on managing diabetes throughout these various stages.
This document discusses insulin therapy for diabetes. It begins with a brief history of insulin's discovery in 1921 by Banting and Best in Toronto. It then covers normal insulin secretion patterns and the types of insulin available, including rapid-acting, short-acting, intermediate-acting, premixed, basal, and extended long-acting analog insulins. The document discusses initiating and titrating insulin using the ADA treatment algorithm, beginning with basal insulin and adding bolus insulin as needed based on blood glucose levels and HbA1c targets. It also covers starting and adjusting premixed insulin doses.
This document discusses insulin pens and proper injection techniques. It begins by introducing insulin pens and their importance for precise insulin dosing. It then discusses barriers to initiating insulin therapy, including concerns about hypoglycemia, weight gain, and complexity of treatment. The document provides tips for proper insulin pen use, such as priming the pen before injections, holding the needle in place for 10 seconds after injecting, and disposing of needles properly. It addresses issues like insulin dripping or leaking after injection and provides solutions. The key message is on the importance of proper injection technique for optimal insulin dosing and outcomes.
Ueda2016 type 1 diabetes guidelines - hesham el hefnawyueda2015
This document provides information about Prof. M. Hesham El Hefnawy, the head of the National Institute of Diabetes & Endocrinology in Egypt. It gives details about his credentials and experience in diabetes research and management. It then discusses guidelines for managing type 1 diabetes, including using insulin therapy, nutritional education, exercise, and treating complications. It provides guidance on initial insulin dosing, separating doses into basal and bolus components. It also offers tips on titrating insulin doses based on glucose monitoring and factors affecting insulin needs. The document aims to help optimize type 1 diabetes management through individualized care plans.
This document discusses tobacco and noncommunicable diseases (NCDs) in Egypt. It notes that over 170,000 Egyptians die each year from tobacco-related illnesses. Tobacco use also results in significant economic costs for healthcare and lost productivity. The four main NCDs - cardiovascular disease, diabetes, cancer and chronic respiratory disease - all share four main modifiable risk factors, one of which is tobacco use. The document outlines Egypt's ratification of the WHO Framework Convention on Tobacco Control and implementation of Law 157/2007 to increase tobacco taxes, expand health warnings on packaging, ban indoor smoking and restrict youth access.
Ueda2016 thyroid nodule in practice - khaled el hadidyueda2015
The document discusses thyroid nodules and guidelines for their evaluation and management. It provides definitions of thyroid nodules and discusses their prevalence in the population. Risk factors for malignancy are outlined. The American Thyroid Association guidelines from 2009 and 2015 are summarized, including recommendations on ultrasound characteristics warranting biopsy and nodule size thresholds for biopsy consideration. Systems for stratifying nodules based on ultrasound features, such as the TI-RADS system, are also covered briefly.
Ueda2016 the role of gut microbiota in the pathogenesis of obesity & tdm2...ueda2015
The document discusses the role of gut microbiota in the pathogenesis of obesity and type 2 diabetes mellitus (TDM2). It provides an introduction to gut microbiota, symbiotic relationships, evidence connecting gut microbiota to obesity and TDM2, and potential mechanisms of causality. Key points include that gut microbiota composition differs between obese and lean individuals, transplantation studies show gut microbiota can influence weight gain, and mechanisms may involve energy harvest from food, production of short chain fatty acids, effects on hormones like GLP-1, and low-grade inflammation from bacterial translocation.
Ueda2016 the agenda for ncd prevention and control - samer jabbourueda2015
This document discusses non-communicable diseases (NCDs) in the Eastern Mediterranean region. It finds that NCDs account for over half of all deaths in the region. The top four NCDs - cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes - cause over 2.2 million deaths annually. The document then outlines the WHO's agenda and framework for NCD prevention and control. This includes strategic interventions related to governance, prevention, surveillance, and healthcare. It emphasizes that both population-level prevention efforts and improved healthcare services will be needed to achieve global NCD reduction targets.
Ueda2016 recommendations for management of diabetes during ramadan - update 2...ueda2015
This document provides recommendations for managing diabetes during Ramadan, including:
1. Individuals with diabetes who wish to fast should undergo a medical assessment prior to Ramadan to adjust medications and ensure safety.
2. Education on self-monitoring, nutrition, exercise and medication adjustments can help diabetics fast safely. Hypoglycemia and hyperglycemia risks are increased and must be managed.
3. For type 2 diabetics, metformin, DPP-4 inhibitors, glitazones and short-acting insulin secretagogues are preferred treatment options during Ramadan due to lower hypoglycemia risks compared to sulfonylureas. Basal-bolus regimens are recommended
Ueda2016 prevention of diabetes,the role of patients’ associations -mominaat ...ueda2015
- Prevention of diabetes is a priority in Azerbaijan due to rising rates of diabetes from 40,000 cases in 1995 to 240,000 cases in 2015. Contributing factors include high rates of overweight and obesity in women.
- The Azerbaijan Diabetes Society (ADS) works to promote diabetes prevention through public awareness campaigns, education in schools, and establishing diabetes care centers.
- ADS initiatives include testing students for diabetes risk, running a "Healthy Lifestyle - Healthy Generation" campaign to promote healthy eating and exercise in schools, and making policy recommendations to the government.
This document discusses some pitfalls in the treatment of diabetic foot ulcers. It begins by stating that no lesion should be underestimated. It then covers diabetic foot infection, describing the differences between contamination, colonization, and infection. Grading of foot wound infection from mild to severe is explained using the IDSA IWGDF classification system. The importance of debriding wounds with necrotic tissue is highlighted. Different dressings are discussed, noting that keeping wounds dry is no longer the preferred treatment and that some older antiseptics like Mercurochrome are no longer recommended. The concept of wound bed preparation focusing on issues of non-viable tissue, infection, moisture balance, and non-advancing edges is introduced
Ueda2016 non pharmacological diabetes management - emad hamedueda2015
The document compares diabetes management in a standard clinic versus an integrated diabetes center. It discusses several non-pharmacological approaches to diabetes care including self-management education, physical activity, medical nutrition therapy, stress management, foot care education, smoking cessation, and immunization. It emphasizes that these modalities are effective, safe, and can be affordable ways to manage diabetes when offered to patients.
This document discusses non-communicable diseases (NCDs) and NCD alliances. It notes that 57% of deaths in the Eastern Mediterranean region are due to NCDs like heart disease, diabetes, and cancer. Risk factors for NCDs like tobacco use, unhealthy diets, and physical inactivity are on the rise globally. In 2011, the UN held its first high-level meeting on NCDs which resulted in a political declaration and commitments to address the growing NCD burden. The document then discusses the role of the NCD Alliance, a civil society network, in supporting a global response to NCDs at national and regional levels including the formation of country-level alliances.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
1. Prof. Ashraf Talaat ,MD.
Internal Medicine Departement
Endocrinology,Diabetes&Metabolism Unit
Chief of Nephrology&Renal Dialysis Units
Banha Faculty of Medicine
Banha University
Egypt
Diabetes & The Liver
from old concepts to new evidence
UEDA,2016 ,Aswan
6. Agenda
Magnitude of the problem.
Effect of CLD on diabetes.
Effect of diabetes on CLD.
Anti-diabetic agents and the normal liver.
Management of hyperglycemia in CLD:
o In patients with compensated CLD.
o In patients with decompensated CLD.
8. Prevalence of diabetes in adults
(20-79 years)
387 million people have diabetes in the world and more
than 37 million people in the Middle East and North Africa
(MENA)Region, by 2035 this will rise to 68 million.
The Middle East and North Africa (MENA)Region,
1 in 10 adults have diabetes; the Region has the highest
prevalence of diabetes.
in Egypt in 2014 , There were over 7.5 million cases of
diabetes
International Diabetes Federation. IDF Diabetes Atlas, 6th edition. Brussels.
9. The rates of diabetes in Egypt has significantly
increased exceeding international rates, (IDF
,2016).
Egypt is now ranked eighth highest in the world
in terms of the disease.
10. Diabetes and CLD are common
conditions in Egypt.
The 2 conditions often coexist.
DM CLD
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
13. Diabetes & Liver diseases
Both problems have an important interaction
considering etiology & the presence of any
problem of each affect the management of the
other.
14. Liver is the main organ concerned with glucose
homeostasis through:
1)Glycogenesis :
In the postprandial state (under effect of insulin)
2) Glycogenolysis & Gluconeogenesis :
In the fasting state (mainly under effect of glucagon)
15. ??????????
What is the relationship
between liver diseases &
abnormalities of glucose
homeostasis
???????
16. Classified into 3 cateogries:
Liver diseases as a consequence of IR/ DM
Abnormalities of glucose metabolism as a
consequence of liver diseases
Diseases causes liver diseases & abnormalities of
glucose metabolism
27. Abnormalities of glucose metabolism as a
consequence of liver diseases :
I) Hypoglycemia : Is rare in liver diseases, however it may occur in:
-Acute liver cell failure and terminal cirrhosis
-Hepatocellular carcinoma
II) Impaired glucose tolerance & DM:
-Hepatogenous DM
-Post-Liver Transplantation
-HCC
28. Hepatogenous DM
(Association of cirrhosis with impaired glucose metabolism)
60% of cirrhotic patients have IGT
20% of cirrhotic patients have DM
This is different from T2DM because it occurs in absence of risk factors e.g. age,
BMI or family history.
The mechanism underlying hepatogenous DM is:
“ insulin resistance”,
may be due to:
1. Hyperinsulinemia
2. Elevated level of FFA.
3. Chronic inflammation (through effect of inflammatory cytokines e.g. IL1,IL6 and
TNF-alpha).
30. Mechanisms of IGT/DM in CHC infection
A) Insulin Resistance .
B) Defective Insulin Secrection:
-Direct autoimmune damage of B-cells by the virus.
- Interferon
The incidence of new onset DM in CHC patients who achieved
SVR after IFN therapy is lower than the incidence in who failed
therapy.
31. Adverse impact of IR/T2DM on outcome in CHC
Natural History:
The association between IR/T2DM and CHC leads to more progression to liver
cirrhosis.
Response to therapy:
IR/T2DM patients are associated with reduced rates of RVR as well as SVR in CHC
treated patients.
Improvement of insulin sensitivity by life style modification and drugs
(metformin OR TZD) has improved the responsiveness of standard
antiviral therapy in non-diabetic patients especially in genotype 4 .
.
33. Agenda
Magnitude of the problem.
Effect of CLD on diabetes.
Effect of diabetes on CLD.
Anti-diabetic agents and the normal liver.
Management of hyperglycemia in CLD:
o In patients with compensated CLD.
o In patients with decompensated CLD.
34. Khan et al. Postgrad Med. 2012 Jul;124:130-7.
↑ fibrogenesis
& progression
to cirrhosis
↑ risk of liver failure
↑ risk of HCC
↑ premature mortality.↓ response to
antiviral ₨
CLD
35. Agenda
Magnitude of the problem.
Effect of CLD on diabetes.
Effect of diabetes on CLD.
Anti-diabetic agents and the normal liver.
Management of hyperglycemia in CLD:
o In patients with compensated CLD.
o In patients with decompensated CLD.
40. Insulin:
Insulin is metabolized by insulinase in
the liver and kidney.
About 50% of insulin is removed, by
‘first-pass’ hepatic extraction.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
41. Statins:
May cause elevation in liver enzymes:
o Minor: rarely exceeds 3 times ULN.
o Transient without long-term effects.
o Severe liver damage is very rare.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
42. Agenda
Magnitude of the problem.
Effect of CLD on Diabetes.
Effect of diabetes on CLD.
Anti-diabetic agents and the normal liver.
Management of diabetes in CLD:
o In patients with compensated CLD.
o In patients with decompensated CLD.
43. Management of DM in Liver diseases
It depends on:
1)Severity of liver disease:
Assessed by
Child-Pugh Classification
Model for End-stage Liver Disease (MELD)
2) Activity of liver disease:
Assessed by the liver of transaminases (markers of liver cell injury).
The injury is considered significant if the level of ALT is 2.5 fold than normal.
3)Type and cause of diabetes.
4)Other factors :
e.g. age of patient, severity of diabetes, occupation, socioeconomic state,
presence of other diabetic complications
44. Glycemic target:
Individualized
Moscatiello et al. Nutrition, Metabolism & Cardiovascular Diseases (2007) 17, 63-70
Compensated CLD
with good life expectancy
Decompensated CLD
with poor life expectancy
More aggressive target Non-aggressive target
45. What are the signs of decompensation?
Ascites.
Coagulopathy.
Encephalopathy.
Moscatiello et al. Nutrition, Metabolism & Cardiovascular Diseases (2007) 17, 63-70
46. Agenda
Magnitude of the problem.
Effect of CLD on diabetes.
Effect of diabetes on CLD.
Anti-diabetic agents and the normal liver.
Management of diabetes in CLD:
o In patients with compensated CLD.
o In patients with decompensated CLD.
47. In patients with compensated CLD:
Lifestyle modification:
Mediterranean diet:
o High complex CHO.
o High monounsaturated fats.
o Low amounts of red meat.
Weight loss: in patients with NAFLD.
48. In patients with compensated CLD:
Pharmacologic therapy:
The same as that without CLD … Why?
o Drug metabolism is altered (only
altered in patients with liver failure).
at higher risk for hepatotoxicity.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
49. In patients with compensated CLD:
Metformin:
First-line therapy in most patients.
Stop:
o If liver or renal functions deteriorated.
o In the setting of acute illness.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
50. Can we use metformin in
compensated patients with HCV?
Nkontchou et al. J Clin Endocrinol Metab, August 2011, 96(8):2601–2608
?Conclusions: use of metformin was associated
with reduced incidence of HCC & mortality.
In another study adding metformin to
interferon & ribavirin was associated with a
better response to anti-viral therapy.
51. Can we use metformin in
compensated patients with NAFLD?
Yes.
It is safe and may be even beneficial.
Romero-Gómez et al. Hepatology 2009; 50: 1702-1708.
52. In patients with compensated CLD:
Sulfonylureas:
Safe to use.
The main side effect is hypoglycemia.
SUs with a short half-life such as glipizide
are preferred.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
53. In patients with compensated CLD:
Repaglinide:
Safe to use.
Less hypoglycemia than SUs.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
54. In patients with compensated CLD:
Pioglitazone:
In patients with NAFLD may lead to
improvement in ALT and liver histology.
Do Not use if ALT ≥ 3 times ULN.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
55. In patients with compensated CLD:
DPP-4 inhibitors:
Sitagliptin & saxagliptin can be safely
used without dose adjustment.
Vildagliptin is not approved in patients
with hepatic insufficiency.
Khan et al. Postgrad Med. 2012 Jul;124:130-7.
57. Sglt2 i
• Sodium-glucose co-transporter 2 (SGLT2)
• inhibitors work by blocking the reabsorption
of filtered glucose in the kidneys.
.This leads to glucosuria and improved
glycemic control.
58. Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Clinical trials showed an in incidence of liver damage and
breast and bladder cancers amongst those taking the drug but
not to a high enough degree to indicate a clear increase in risk.
Sodium/glucose co-transporter 2 inhibitors as highly suitable
for the inhibition of progression of non-alcoholic fatty liver
disease (NAFLD), non-alcoholic steatohepatitis (NASH),
alcoholic fatty liver disease, diabetic fatty liver .
59.
60.
61. In patients with compensated CLD:
Insulin:
Higher doses may be needed due to
insulin resistance.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
62. In patients with compensated CLD:
Statins:
Safe in patients with compensated CLD.
Especially helpful in patients with NAFLD.
May be hepato-protective in patients
with HCV.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
63. In patients with compensated CLD:
Aspirin:
Safe to use.
The cardio-protective dose (75-150 mg)
is not Hepatotoxic.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
64. Agenda
Magnitude of the problem.
Effect of CLD on diabetes.
Effect of diabetes on CLD.
Anti-diabetic agents and the normal liver.
Management of hyperglycemia in CLD:
o In patients with compensated CLD.
o In patients with decompensated CLD.
65. Glycemic target in decompensated CLD:
The objective is just to ↓ the osmotic
symptoms related to diabetes .. Why?
• Prognosis depends on the complications
of the primary hepatic disease, rather
than diabetes complications.
Moscatiello et al. Nutrition, Metabolism & Cardiovascular Diseases (2007) 17, 63-70
66. In patients with decompensated CLD:
Lifestyle modification:
>50% of patients are malnourished.
Avoid dietary restriction as it may result in:
o Hypo-albuminemia.
o Coagulopathy due to ↓ vitamin K intake.
o Worsen overall prognosis.
67. In patients with decompensated CLD:
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
Metformin
SU & Repaglinide
Pioglitazone
DPP-4 inhibitors
Aspirin & statins
Fear of lactic acidosis
Fear of hypoglycemia
Fear of hepatotoxicity
Limited experience
No prognostic benefit
69. In patients with decompensated CLD:
Insulin:
The safest and most effective therapy.
The main risk is severe hypoglycemia.
Careful glucose monitoring is needed.
Dose may be decreased due to reduced
hepatic breakdown of insulin.
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
70. In patients with decompensated CLD:
Insulin Regimen
Meal-related insulin administration
00.00 08.00 12.00 18.00 24.00
Regular
Lispro
Aspart
Glulisine
71. Why we don’t usually need basal insulin
in patients with decompensated CLD?
Tolman et al. Diabetes Care. 2007 Mar;30:734-43.
Glycemic profile is characterized by
low fasting plasma glucose due to
↓ hepatic glucose production.
72. In patients with decompensated CLD:
Follow up of glycemic control:
o SMBG is preferred over HbA1c …. WHY?
Cirrhosis (± hypersplenism) reduces
RCSs life-span false low HbA1c.
73. Summary
Type 2 diabetes is associated with a large number of liver
disorders including elevated liver enzymes, fatty liver
disease, cirrhosis, hepatocellular carcinoma. In addition,
there is an unexplained association with HCV.
The presence of liver disease (unless decompensated) has
little implication for the specific treatment of diabetes, and
the presence of diabetes has little implication for the specific
treatment of liver disease.
Patients with decompensated liver disease are more
susceptible to hypoglycemia and require careful monitoring.
There continues to be a need for long-term placebo
controlled trials for the treatment of NAFLD and for the
treatment of diabetes in patients with liver disease.
76. Metformin
SU & Repaglinide
Pioglitazone
DPP-4 inhibitors
Insulin
In patients with compensated CLD
Stop if liver or renal
function deteriorated.
Be aware of hypoglycemia
Avoid if ALT level ≥ 3 ULN
Avoid vildagliptin
High dose may be needed
77. In patients with decompensated CLD
Insulin in the best line of therapy
93. Position Statement of the American Diabetes Association
(ADA) & the European Association for the Study of
Diabetes (EASD)
Hypoglycaemia in type 2 diabetes was long thought to
be a trivial issue , as it occurs less commonly than in type
1 diabetes. However, there is emerging concern
based mainly on the results of recent clinical trials and
some cross-sectional evidence of increased risk of
brain dysfunction in those with repeated episodes
93
Diabetes Care, Diabetologia. 19 April 2012